Mesoblast Limited (OTCMKTS:MEOBF – Get Free Report)’s stock price traded down 8.8% during mid-day trading on Monday . The company traded as low as $1.55 and last traded at $1.55. 2,000 shares changed hands during mid-day trading, a decline of 20% from the average session volume of 2,486 shares. The stock had previously closed at $1.70.
Mesoblast Price Performance
The business’s 50 day moving average is $1.66 and its 200-day moving average is $1.61.
Mesoblast Company Profile
Mesoblast Limited (OTCMKTS:MEOBF) is a global leader in regenerative medicine focused on the development and commercialization of innovative allogeneic cell therapies. The company’s proprietary platform harnesses mesenchymal lineage adult stem cells to address a range of inflammatory and immunological conditions. Mesoblast’s pipeline includes multiple late-stage and marketed products that target serious diseases with high unmet medical needs.
The company’s lead product, remestemcel-L (Ryvicor/Ryoncil), is under development for the treatment of steroid-refractory acute graft versus host disease in pediatric patients and has received conditional approval for certain indications in Japan.
Read More
- Five stocks we like better than Mesoblast
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.
